DCM
CTMX icon

Dupont Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Dupont Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-66,285
Closed -$512K – 1749
2021
Q1 		$512K Buy
+66,285
New +$525K 0.01% 898
2019
Q4 		– Sell
-33,577
Closed -$248K – 1249
2019
Q3 		$248K Buy
+33,577
New +$331K 0.01% 1051
2018
Q4 		– Sell
-15,088
Closed -$279K – 1175
2018
Q3 		$279K Hold
15,088
– – 0.01% 833
2018
Q2 		$345K Buy
+15,088
New +$385K 0.01% 794

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Dupont Capital Management's CTMX Position: Q2 2021 in Review

Dupont Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 66,285 shares — an estimated $512K sold.

Dupont Capital Management first reported a position in CTMX in Q2 2018 and held it in 4 quarters. The position peaked at $512K in Q1 2021. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • Dupont Capital Management reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Dupont Capital Management sold 66,285 CytomX Therapeutics shares in Q2 2021, an estimated $512K.
  • Dupont Capital Management first reported a position in CytomX Therapeutics in Q2 2018 and held it in 4 quarters.
  • Dupont Capital Management's CytomX Therapeutics position peaked at $512K in Q1 2021.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on Dupont Capital Management's 13F filing for Q2 2021, filed 30 Jul 2021.